Deborah Wise
Oncology · Kettering, OHNPI 1134340599
Payments from drug & device makers
What this record shows
8 manufacturers reported payments, led by Gilead at 24.9% of the total. 2025 is the largest year on record at $403, 4.7 times the $86 reported in 2022.
Across 9 payments — averaging $77.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$174
- Amgen$125
- Johnson & Johnson$92
- Genmab U.S., Inc.$87
- Incyte Corporation$86
- Sobi, Inc$84
- plus $49 from 2 others
What the payments were for
- Food & beverage$34650%
- Education$35250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 2 | $174 |
| Amgen | 1 | $125 |
| Johnson & Johnson | 1 | $92 |
| Genmab U.S., Inc. | 1 | $87 |
| Incyte Corporation | 1 | $86 |
| Sobi, Inc | 1 | $84 |
| AbbVie | 1 | $28 |
| Adaptive Biotechnologies Corporation | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$698 in reported general payments places this provider in the 60th percentile of 20 oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 21 | $16,817 |
| Ondansetron Hcl | 11 | $1,862 |
| Exemestane | 13 | $1,315 |
| Letrozole | 44 | $757 |
| Anastrozole | 23 | $167 |
| Klor-Con M20Potassium Chloride | 11 | $88 |
Paid to pharmacies, not to this prescriber.
Other oncology in Kettering
- Jill ReeseBeavercreek$7K
- Tammie ThompsonCanton$2K
- Anne KolenicCleveland$2K
- Shelly BrownColumbus$1K
- Deana KehresSandusky$921
- Patricia AdamsCincinnati$752
- Arleen WuestefeldCincinnati$709
- Lisa SmithColumbus$536
- Gail BujorianBarberton$483
- Diana KariusCleveland$464
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.